Useful Advices - Business

Cultural Intelligence or CQ is a new domain of intelligence that is increasingly relevant to today's global economy. As diversity

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

is here to stay - brought about by opportunities of global expansion and presence - traits like Intelligence Quotient [IQ] and E

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

motional Quotient [EQ] are no longer suffice.

CQ can be distinguished through three sources: Cognitive,

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

Motivation and Behaviour. These sources enable an Individual to distinguish different sets of behaviour

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

:
* Behaviours produced by the culture in question
* Behaviours that are peculiar to individuals
* Behaviours foun

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

in all human beings

Moreover, customers and markets have become more wide-ranging and sophisticated that it is critical

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

to maintain your organization's Competitive Advantage and Market Leadership. The emergence of

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

arkets like China, India and Vietnam impact global economies; hence it is expected of both organizations and employees to develop

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

and assume a repertoire of skilled behaviours in order to interact effectively across cultural boundaries. Not just competently,

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

but also intelligently.

With the ever-increasing cross-border travelling and short-term international assignments that have beco

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

me commonplace; the organization should ensure that procedures are in place before embarking on a global presence, for instance:<

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

br> * the hiring of culturally-competent employees
* cultivate and encourage a cultural-sensitive<

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

strong> work environment
* communicate in globally-understood English
* adapting to a global e

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

nvironment company-wide, inclusive overseas subsidiaries

The above emphasized factors are not exhaustive althou

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

h they are the more easily identified; as well as more commonly cited. Any organization that has overseas presence outside its ho

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

me market - by way of subsidiaries, joint ventures or representative offices - certainly has experienced repatriating staff who s

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

mply could not adapt to strange or foreign environments. Or receiving "complaints" about how foreign business transactions are no

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

t done accordingly to ways they are familiar with, but quoted as "idiosyncratic" too.

Likewise, the International Assignee who l

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

oks forward to an overseas experience would wish to succeed in his assignment. By equipping himself with the necessary CQ skills,

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

chances of career promotion are definitely higher and favourable - besides becoming a better and culturally-sensitive individual

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

Tags

Links

Useful Advices - Cultural Intelligence: Why Is It Crucial In Today's Globalized Economy?

Related Articles: